News Quantified

RLMD – relmada therapeutics, inc. (US:NASDAQ)

Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

Relmada Therapeutics, Inc. (NASDAQ: RLMD) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock, up previously from $3.50.

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Insider Spends US$395k Buying More Shares In Relmada Therapeutics [Yahoo! Finance]

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}